On March 23, 2026, Drugs Made In America Acquisition Corp. (the "Company") announced the issuance of an interim convertible note to BV Advisory Partners, LLC (the "Investor") for a principal amount of $100,000. This interim loan is part of a larger financing plan, which aims to raise a total of $500,000 as outlined in the Definitive Interim Investment and Sponsor Transition Agreement. The interim note is set to mature in six months unless converted or credited towards the definitive financing. The Company intends to utilize the proceeds from this loan for various expenses related to a potential business combination, although no agreement for such a combination has been finalized yet. The terms of the note allow the Investor to convert the outstanding principal into shares of the combined entity at a 35% discount to the market price at the time of conversion, which could significantly impact the capital structure of the Company. The announcement of this financing is expected to have a small positive effect on the stock price as it indicates proactive steps towards securing necessary funding for future operations and potential mergers.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.